In a survey of the LSIs, 85% reported that the trial has helped standardize the management of biochemically recurrent, oligorecurrent, and de novo oligometastatic prostate cancer patients; 77% reported that participating in VA STARPORT helped improve the technical aspects of the clinical radiotherapy program; 62% reported that participating in VA STARPORT has allowed for the improved use of somatic and germline sequencing; and 43% reported participating in VA STARPORT helped them obtain access to PSMA PET/CT imaging quicker or more easily. This evidence concerns the gene FOLH1 and prostate cancer.